Moleculin Biotech CS (MBRX) Stock Price, Quote & News

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology

Sector: Healthcare

Phone: 713 300 5160

Website: moleculin.com

Address:

5300 Memorial Drive, Suite 950, Houston, United States

_Moony4x Feb. 25 at 7:46 PM

$MBRX $KXIN $PLRZ $PMN s

0 · Reply

StocktwitsAragorn Feb. 25 at 4:55 PM

$MBRX https://www.stockscores.com/charts/charts/?ticker=mbrx Should at least close the cap at 5.00

0 · Reply

Brokechump Feb. 24 at 10:49 PM

$MBRX

0 · Reply

StocktwitsAragorn Feb. 24 at 9:29 PM

$MBRX https://www.stockscores.com/charts/charts/?ticker=mbrx Worth a long position now!

0 · Reply

IVALTE Feb. 24 at 9:18 PM

$MBRX putos vendehumos

0 · Reply

kyly2 Feb. 24 at 3:58 PM

$MBRX Subirá

0 · Reply

johndoe40 Feb. 23 at 10:07 PM

$MBRX

0 · Reply

Stormra Feb. 23 at 4:58 PM

$MBRX Let's go.......

1 · Reply

_Moony4x Feb. 23 at 12:28 PM

$CBSH $NIVF $MBRX $KXIN

0 · Reply

Herbgator Feb. 23 at 6:05 AM

$MBRX Been in this since 2019. Been selling massive loses to tax shield huge gains elsewhere the past two years and that’s the only reason I hold any today . Very poor execution by this management team. Not worth time for a class action! If they were in charge of the Sahara Desert, they’d run out of sand. If they get lucky on the ‘Miracle trial’ -pre-approval to satisfy the new FDA guidelines due out soon, best course of action is to try and sell all their assets asap because you sure as hell don’t want them trying to negotiate/navigate going to market on any business plan- especially going it alone. IMHO

0 · Reply

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

Feb 18, 2026, 8:20 AM EST - 8 days ago

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Feb 17, 2026, 8:35 AM EST - 9 days ago

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

Feb 13, 2026, 8:32 AM EST - 13 days ago

Moleculin Launches CEO Corner Platform to Share Strategic Insights

Feb 5, 2026, 9:15 AM EST - 21 days ago

Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Jan 13, 2026, 8:55 AM EST - 6 weeks ago

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

Jan 12, 2026, 8:36 AM EST - 6 weeks ago

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

Dec 17, 2025, 8:31 AM EST - 2 months ago

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Dec 10, 2025, 8:30 AM EST - 2 months ago

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Dec 9, 2025, 8:07 AM EST - 2 months ago

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Dec 8, 2025, 8:21 AM EST - 2 months ago

Moleculin Announces New Annamycin Collaboration in Brain Tumors

Nov 26, 2025, 9:15 AM EST - 3 months ago

Moleculin to Participate in the Virtual Investor Closing Bell Series

Nov 26, 2025, 9:00 AM EST - 3 months ago

Moleculin Announces Reverse Stock Split

Nov 13, 2025, 8:36 AM EST - 3 months ago

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Nov 12, 2025, 8:37 AM EST - 3 months ago

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Oct 30, 2025, 8:40 AM EDT - 4 months ago

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

Oct 29, 2025, 8:35 AM EDT - 4 months ago

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

Oct 23, 2025, 8:00 AM EDT - 4 months ago

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Sep 25, 2025, 8:35 AM EDT - 5 months ago

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Sep 9, 2025, 8:45 AM EDT - 6 months ago

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Sep 8, 2025, 8:30 AM EDT - 6 months ago

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Aug 28, 2025, 8:30 AM EDT - 6 months ago

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Aug 27, 2025, 8:45 AM EDT - 6 months ago

Moleculin Issues New Positive AML Overall Survival Data:

Aug 14, 2025, 9:15 AM EDT - 7 months ago

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 13, 2025, 8:05 AM EDT - 7 months ago

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Aug 6, 2025, 8:40 AM EDT - 7 months ago

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Jul 30, 2025, 8:35 AM EDT - 7 months ago

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Jul 22, 2025, 8:45 AM EDT - 7 months ago

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 17, 2025, 8:25 AM EDT - 8 months ago

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Jul 9, 2025, 8:35 AM EDT - 8 months ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Jun 20, 2025, 9:20 AM EDT - 8 months ago

Moleculin Announces $5.9 Million Public Offering

Jun 18, 2025, 7:45 AM EDT - 9 months ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Jun 18, 2025, 7:30 AM EDT - 9 months ago

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Jun 5, 2025, 8:00 AM EDT - 9 months ago

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Jun 4, 2025, 8:45 AM EDT - 9 months ago

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

May 14, 2025, 12:20 PM EDT - 10 months ago

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:30 AM EDT - 10 months ago

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 8:40 AM EDT - 10 months ago

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 7, 2025, 9:00 AM EDT - 10 months ago

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

May 6, 2025, 9:00 AM EDT - 10 months ago

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

May 5, 2025, 8:45 AM EDT - 10 months ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Apr 29, 2025, 8:35 AM EDT - 10 months ago

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Apr 17, 2025, 8:30 AM EDT - 11 months ago

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 1, 2025, 8:30 AM EDT - 11 months ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Mar 24, 2025, 10:50 AM EDT - 1 year ago

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 7:05 AM EDT - 1 year ago

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 19, 2025, 8:05 AM EDT - 1 year ago

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Mar 11, 2025, 8:45 AM EDT - 1 year ago

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Mar 10, 2025, 8:45 AM EDT - 1 year ago

Moleculin to Present at the 37th Annual ROTH Conference

Mar 6, 2025, 8:30 AM EST - 1 year ago

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

_Moony4x Feb. 25 at 7:46 PM

$MBRX $KXIN $PLRZ $PMN s

0 · Reply

StocktwitsAragorn Feb. 25 at 4:55 PM

$MBRX https://www.stockscores.com/charts/charts/?ticker=mbrx Should at least close the cap at 5.00

0 · Reply

Brokechump Feb. 24 at 10:49 PM

$MBRX

0 · Reply

StocktwitsAragorn Feb. 24 at 9:29 PM

$MBRX https://www.stockscores.com/charts/charts/?ticker=mbrx Worth a long position now!

0 · Reply

IVALTE Feb. 24 at 9:18 PM

$MBRX putos vendehumos

0 · Reply

kyly2 Feb. 24 at 3:58 PM

$MBRX Subirá

0 · Reply

johndoe40 Feb. 23 at 10:07 PM

$MBRX

0 · Reply

Stormra Feb. 23 at 4:58 PM

$MBRX Let's go.......

1 · Reply

_Moony4x Feb. 23 at 12:28 PM

$CBSH $NIVF $MBRX $KXIN

0 · Reply

Herbgator Feb. 23 at 6:05 AM

0 · Reply

mokaz1 Feb. 23 at 3:47 AM

$MBRX If the clinical results are statistically significant, I’ll shave my head.

0 · Reply

Kewlpapa Feb. 20 at 8:49 PM

$MBRX got a starter here🍻

0 · Reply

Blocktatch Feb. 20 at 7:54 PM

$MBRX another RS is coming soon

1 · Reply

kyly2 Feb. 20 at 5:49 PM

$MBRX Perdonen. Creo que sigue valiendo mucha pasta

1 · Reply

kyly2 Feb. 20 at 5:22 PM

$MBRX Que pasó?

0 · Reply

IVALTE Feb. 20 at 5:14 PM

$MBRX esto se va a la mierda

0 · Reply

Ventureville Feb. 20 at 3:57 PM

Q1 2026 is already lighting up biotech. $MBRX accelerating its AML trial. $KRYS beating on earnings. Multiple FDA decisions lined up across the sector. When biotech momentum builds, small caps move fast. $BIOV.CSE $BVAXF with HapTenix and BVX-0918 in ovarian cancer sits right in that wave. Rotation into biotech does not trickle. It snaps.

0 · Reply

jim64 Feb. 20 at 11:30 AM

$MBRX Wally has done this over and over again for years. Gets the stock up and immediately dilutes.

1 · Reply

APEDM Feb. 20 at 10:50 AM

$MBRX Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $20

0 · Reply

Shuqishuqi Feb. 20 at 7:45 AM

$MBRX it has to go back to $4.X I believe

0 · Reply

Shuqishuqi Feb. 20 at 7:45 AM

$MBRX definitely

0 · Reply

MarketBeastLive Feb. 20 at 4:00 AM

$MBRX watching

0 · Reply

Market Cap	4.99M
Revenue (ttm)	0.00
Net Income (ttm)	-21.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	168,700
Avg Vol	309,914
Day's Range	N/A - N/A
Shares Out	2.04M
Stochastic %K	11%
Beta	1.65
Analysts	Strong Sell
Price Target	$24.33